Early Detection Market Target potential customers in oncology and neurology spaces looking for non-invasive early detection tools. Highlight iCAP’s ability to convert low-abundance blood biomarkers into measurable cell responses, addressing a key unmet need in cancer and Alzheimer’s disease screening.

Clinical Validation Position PreCyte as a partner for translational research and pilot studies funded by government and private grants. Leverage past NIH and SBIR activities to attract collaborations with academic medical centers seeking proof-of-concept data for diagnostic assays.

Strategic Partnerships Target large diagnostics firms and CROs focusing on blood-based biomarkers who could integrate iCAP as a platform technology or co-develop companion diagnostics for cancer screening programs.

Market Entry Speed Emphasize the scalable cloud-enabled data pipeline and machine learning component to accelerate biomarker signal interpretation, offering faster study design and analysis for early-detection panels.

Funding Readiness Leverage demonstrated government funding and a modest revenue base to pursue joint development agreements and early-access programs with biopharma, device developers, and diagnostics companies seeking novel screening solutions.